Drug intelligence / Profile preview

ONO-5129

Development stage: Phase 2
Lead developer: Ono Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

ONO-5129 is a small molecule drug developed by Ono Pharmaceutical. It acts as a dual agonist of peroxisome proliferator-activated receptor alpha (PPARα) and peroxisome proliferator-activated receptor gamma (PPARγ). These nuclear receptors play key roles in regulating lipid metabolism, glucose homeostasis, and insulin sensitivity. Dual PPARα/γ agonists have been investigated for the treatment of metabolic diseases such as type 2 diabetes mellitus. Clinical trials with ONO-5129 have focused on evaluating its efficacy, safety, and pharmacokinetics in patients with type 2 diabetes mellitus[1][2][3][4].

Other names: ONO 5129ONO5129ONO-5129

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on ONO-5129.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONO-5129.

Explore the full profile